In Brief
Refine Search
Biotechnology
Massachusetts, USA-based biotech Viridian Therapeutics has submitted paperwork for a public offering of common and preferred stock. 21 January 2024
Biotechnology
Beijing-based biotech Sinovac has received a partial tender offer from Alternative Liquidity, to acquire up to 10,000,000 common shares at $0.03 per share. 21 January 2024
Biotechnology
Swiss contract development and manufacturing organization (CDMO) Lonza has cut around 200 jobs at a manufacturing facility in California, USA. 19 January 2024
Pharmaceutical
USA-based gastroenterology specialist Ironwood Pharmaceuticals announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology. 15 January 2024
Biotechnology
US drugmaker Vertex Pharmaceuticals has received marketing approval from the Saudi Arabia’s Food and Drug Authority (SFDA) for its Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). 13 January 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), Merck & Co’s mega-blockbuster anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. 13 January 2024
Biotechnology
Outlining its goal of five launches over five years to 2028, Vertex Pharmaceuticals chief executive Reshma Kewalramani has presented a corporate update at the JP Morgan Healthcare Conference. 10 January 2024
Biotechnology
Sarepta Therapeutics has provided a corporate update and outlined clinical and commercial progress at the 2024 JP Morgan Healthcare Conference. 10 January 2024
Biotechnology
Gilead Sciences is looking ahead to a “clinical pipeline full of catalysts in 2024,” according to a presentation given to investors at the JP Morgan Healthcare Conference in California. 9 January 2024
Biotechnology
At the JP Morgan Health Conference, Swiss cancer giant Novartis has presented a corporate update, highlighting clinical and commercial progress while outlining its future strategy. 9 January 2024
Biotechnology
Japan’s Eisai and US biotech Biogen announced that their humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. 9 January 2024
Pharmaceutical
California’s Revagenix has closed a series B funding round from core investors Tenmile and Novo Holdings, raising an undisclosed sum. 8 January 2024
Pharmaceutical
Turbine AI, a UK-based biological simulation company building a platform for interpreting human biology in silico, has entered into a collaboration with British pharma major AstraZeneca. 6 January 2024
Biotechnology
A new genomic medicine start-up, Moonwalk Biosciences, has launched in California with $57 million in seed and series A financing. 5 January 2024
Pharmaceutical
Denmark’s Union Therapeutics has said that its chief executive, Kim Kjøller, will be making a presentation at the JP Morgan Healthcare Conference on January 8. 5 January 2024
Biotechnology
German family-owned pharma major Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT. 4 January 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share, offered at a price of $28.50 per share, before underwriting discounts. 3 January 2024
Pharmaceutical
The British business of Italian drugmaker Menarini has been granted marketing authorization for Korserdu (elacestrant) in the UK. 3 January 2024
Biotechnology
US biotech Mersana Therapeutics and Germany’s Merck KGaA have mutually agreed to terminate both the collaboration and commercial license agreement of June 2014 on Dolaflexin between the parties 2 January 2024
Biotechnology
Drug resistance specialist InMed has inked a deal with fellow Chinese firm Escugen, a clinical-stage antibody–drug conjugate (ADC) developer. 2 January 2024
Pharmaceutical
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. 6 June 2025
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Biotechnology
Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III VALIANT study, investigating Aspaveli/Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 6 June 2025
Biotechnology
Japan’s Otsuka today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. 6 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Biotechnology
Texas-based ImmunoPrecise Antibodies, a leader in AI-driven biotherapeutics, closed 22% higher Thursday. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Pharmaceutical
AstraZeneca has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, for adults newly diagnosed with chronic lymphocytic leukemia (CLL). 6 June 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of German pharma major Bayer’s Nubeqa (darolutamide) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
Biotechnology
US gene therapy company RegeNXBio yesterday announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, RegeNXBio’s potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. 6 June 2025
Biotechnology
The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal cell carcinoma patients who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA). 5 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Biotechnology
German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. 5 June 2025
Biotechnology
US rare disease meds developer Sarepta Therapeutics revealed that its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the US Food and Drug Administration. 5 June 2025
Biotechnology
AI-enabled biotech Juvenescence today announced the acquisition of Ro5 Inc, a proprietary AI drug discovery company. 5 June 2025
Biotechnology
US biopharma Cullinan Therapeutics has entered into an agreement with Genrix Bio for an all-indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T-cell engager for everywhere outside Greater China. 5 June 2025
Pharmaceutical
China’s National Medical Products Administration approved its first domestically-developed nine-valent human papillomavirus (HPV) vaccine on Thursday. 5 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze